In patients affected by BC, since gonadotropin-releasing hormone analogues or chemotherapy and/or aromatase inhibitors reduce estrogen levels inducing early menopause, there is the risk of developing CTIBL, regardless of the risk of developing BM in advanced stages of BC [17, 18]. Here, CYP19A1 is linked to breast cancer.